Initiate the MDNA11 Phase 1 clinical trial
Delivered after the deadline (76 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 14 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the initiation of the clinical study is not planned until mid-calendar 2021”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 1/2 ABILITY study of MDNA11 on September 14, 2021, which occurred after the mid-2021 deadline.
-
A Medicenna Therapeutics Corp. 6-K filed 2021-09-14
“Medicenna Therapeutics Corp. ... today announced the initiation of dosing of patients in the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- MDNA11 Phase 1 clinical trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: patient recruitment
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Medicenna Therapeutics Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MDNAF-023723 · Corrections policy